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The ex vivo neurotoxic, myotoxic and cardiotoxic
activity of cucurbituril-based macrocyclic drug
delivery vehicles
Rabbab Oun,a Rafael S. Floriano,a Lyle Isaacs,b Edward G. Rowana and
Nial J. Wheate*c
The cucurbituril family of drug delivery vehicles have been examined for their tissue speciﬁc toxicity using
ex vivo models. Cucurbit[6]uril (CB[6]), cucurbit[7]uril (CB[7]) and the linear cucurbituril-derivative Motor2
were examined for their neuro-, myo- and cardiotoxic activity and compared with β-cyclodextrin. The
protective eﬀect of drug encapsulation by CB[7] was also examined on the platinum-based anticancer
drug cisplatin. The results show that none of the cucurbiturils have statistically measurable neurotoxicity
as measured using mouse sciatic nerve compound action potential. Cucurbituril myotoxicity was
measured by nerve-muscle force of contraction through chemical and electrical stimulation. Motor2 was
found to display no myotoxicity, whereas both CB[6] and CB[7] showed myotoxic activity via a presynaptic
eﬀect. Finally, cardiotoxicity, which was measured by changes in the rate and force of right and left atria
contraction, was observed for all three cucurbiturils. Free cisplatin displays neuro-, myo- and cardiotoxic
activity, consistent with the side-eﬀects seen in the clinic. Whilst CB[7] had no eﬀect on the level of cis-
platin’s neurotoxic activity, drug encapsulation within the macrocycle had a marked reduction in both the
drug’s myo- and cardiotoxic activity. Overall the results are consistent with the relative lack of toxicity dis-
played by these macrocycles in whole animal acute systemic toxicity studies and indicate continued
potential of cucurbiturils as drug delivery vehicles for the reduction of the side eﬀects associated with
platinum-based chemotherapy.
Introduction
Macrocycles are an important class of delivery vehicle that
have the ability to form a range of host–guest complexes with
drugs. This encapsulation can provide many benefits includ-
ing: increased drug solubility, physical and chemical stability,
taste masking, a reduction of drugs’ toxic side eﬀects and
modulation of their cell uptake.1 Furthermore, encapsulation
can also provide controlled release ensuring that a high and
consistent therapeutic concentration is available for a longer
period of time compared to the free drug, thus increasing its
bioavailability.
Although a number of macrocycles have already shown
potential as delivery vehicles, there is still an increasing
demand for a larger and more diverse selection as no one host
is suitable for every drug. The cucurbit[n]urils (CB[n], where
n represents the number of glycoluril units),2,3 cyclodextrins,4,5
and calixarenes6,7 are the three main types of macrocycles that
have been examined as drug delivery vehicles.
Cucurbit[n]urils (Fig. 1), are named for their resemblance
to the shape of a pumpkin (cucurbitaceae). Native CB[n]s are
synthesised from an acid-catalysed condensation reaction and
are structurally made up of repeating glycoluril units linked by
methylene bridges.8 To date the CB[n] family consists of
CB[5–8], CB[10] and CB[14].8–10 All of the CB[n] homologues
(except CB[14]) share a common height of 9.1 Å but diﬀer in
the diameter of their cavities. Cucurbit[14]uril does not have a
normal cavity as a consequence of a twist in its structure, but
instead adopts a figure-of-eight conformation.10 Each native
CB[n] (except CB[14]) contains two hydrophilic carbonyl
portals and a hydrophobic interior and drug encapsulation is
achieved via ion-dipole or hydrogen bonds to the CB[n] portals
and through the hydrophobic eﬀect upon CB[n]-drug host–
guest complex formation.11 Cucurbit[6]uril, CB[7] and CB[8]
are most commonly used in drug delivery as the cavity of CB[5]
is too small for drug incorporation and the cavity of CB[10] is
too large for strong drug binding.1
aStrathclyde Institute of Pharmacy and Biomedical Sciences, University of
Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK
bDepartment of Chemistry and Biochemistry, University of Maryland, College Park,
MD 20742, USA
cFaculty of Pharmacy, The University of Sydney, NSW 2006, Australia.
E-mail: nial.wheate@sydney.edu.au; Fax: +61 2 9351 4391
This journal is © The Royal Society of Chemistry 2014 Toxicol. Res., 2014, 3, 447–455 | 447
Since the structural determination of CB[6] over three
decades ago, several new cucurbituril derivatives have been
developed, including Motor2 (Fig. 1). Whilst Motor2 is not a
macrocycle but a linear chain, in solution it is able to fold to
create a cavity similar to that of the native cucurbit[n]urils. The
anionic charges of Motor2 means it is considerably more water
soluble (18 mM in pure water) than the native cucurbiturils,
and forms stronger bonds with cationic drugs through electro-
static interactions.12
The benefits of encapsulation by the CB[n]s are best
demonstrated by the platinum-based drugs. In a recent study,
it was shown that when encapsulated by CB[7], the anticancer
drug cisplatin was able to overcome its own acquired resist-
ance in an in vivo human tumour xenograft model via a phar-
macokinetic eﬀect.13 Furthermore, encapsulation of the
multinuclear platinum-based drug BBR3571 by CB[7]
increased its maximum tolerated dose by 70% with the encap-
sulated complex being just as anticancer active as the free
drug.14 These results suggest a promising outlook for the use
of CB[n] as drug delivery vehicles. Before CB[n]s can be
approved for use in drug delivery; however, they must not only
demonstrate that they are able to increase the eﬃcacy of the
encapsulated drugs and/or decrease their associated side
eﬀects but that they are also safe in terms of their systemic
and organ specific toxicities.
Various in vitro and in vivo studies have thus far indicated
that CB[n]s and their derivatives are both inert and non-toxic.
Several studies have shown that at concentrations of up to
1 mM,15,16 CB[7] displays no cytotoxic activity in a range of
human and animal cell lines. When administered in vivo CB[7]
has a maximum tolerated dose (MTD) of 250 mg kg−1; intra-
venous injection of CB[n]s is limited more by their solubility
rather than their side-eﬀects. When a mixture of CB[6]–CB[8]
was administered orally the MTD increased to 600 mg kg−1.17
Overall they show little sign of acute systemic toxicity. Motor2,
has also been shown to be relatively non-toxic in human liver
and kidney cells at concentrations up to 10 mM and when
administered intravenously shows no systemic toxic eﬀects at
doses of up to 1230 mg kg−1.12
In comparison, cyclodextrins, which are already approved
for use in drug formulation, have been shown to be relatively
non-toxic with lethal doses (LD50) in rats and mice between 0.3
to 18.8 g kg−1 depending on the type of cyclodextrin and the
route of administration.18 β-Cyclodextrin, which is composed
of seven glucopyranose units, is however known to be nephro-
toxic when delivered intravenously.18
A limitation to these in vitro and in vivo systemic
approaches is that little information can be gathered on the
toxicity of cucurbiturils to specific organs and the mechanism
by which they do so. Therefore, the use of ex vivo toxicological
Fig. 1 The chemical structures of the macrocycles (a) cucurbit[n]uril, (b) n-cyclodextrin, and (c) Motor2.
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models, in which the toxicity of the test compound is deter-
mined on intact whole tissue, can provide crucial and reliable
predictions of the organ toxicity of CB[n]s in the human
body.19,20
In this paper we report the use of ex vivo electrophysiologi-
cal models to study the neurotoxic, myotoxic and cardiotoxic
activity of native CB[n]s and Motor2 compared with β-cyclo-
dextrin. In addition, the eﬀect of CB[7] on the organ specific
toxicity of cisplatin is examined.
Materials and methods
BALB/C mice and Sprague Dawley rats were obtained from
Strathclyde University’s in house breeding colonies that were
originally sourced from Harlan, UK. Baby chicks were supplied
from a breeding hatchery in Scotland (non-schedule 2 sup-
plier). All animals were euthanized in compliance of the Code
of Practice for the Humane Killing of Animals issued by the
UK Home Oﬃce and in accordance with ethical guidelines of
the Strathclyde Institute of Pharmacy and Biomedical Sciences.
Cisplatin, β-cyclodextrin and CB[6] were bought from Sigma-
Aldrich. Cucurbit[7]uril was bought from Dr Anthony Day, Uni-
versity of New South Wales, Australia. Motor2 was synthesised
as previously described.12
Electrophysiological recordings from mouse sciatic nerve
(neurotoxicity)
BALB/C mice weighing between 25–30 g were euthanised with
CO2. The sciatic nerve was carefully dissected from the knee to
where it meets the spinal cord (3–5 cm in length) and
immersed in HEPES-based physiological salt solution of the
following composition: 150 mM NaCl, 5.4 mM KCl, 10 mM
HEPES, 12 mM NaHCO3, 0.4 mM KH2PO4, 1.2 mM MgCl2,
2.5 mM CaCl2, 10 mM glucose, pH 7.4. The sciatic nerve was
then de-sheathed under a stereo-microscope and laid across
three inter-connecting chambers with ∼70% of the nerve
coiled in the middle chamber. The three chambers were filled
with HEPES-based physiological salt solution to cover the
nerve and electrical isolation between the three chambers was
achieved with Vaseline. Electrical connections were made from
the central chamber to one end chamber by means of Ag/AgCl
electrodes. The remaining third chamber contained two plati-
num electrodes connected to a pulse generator. The middle
chamber was connected to electrical grounds and the voltage
from the third chamber was measured by a high input resist-
ance amplifier. Electrical impulses were supplied to the nerve
by a Grass S88 stimulator (0.4 Hz, 0.05 ms duration, 30 V) via a
SIU 5A stimulus isolation unit (Grass Instrument Co. Quincy,
MA, USA). Signals were amplified with a CED 1902 transducer
(Cambridge Electronic Design, Cambridge, England), digitised
with an analogue digital converter (DigiData 1200 Interface,
Axon Instruments, Scotland), and analysed using Microsoft
windows-based computer electrophysiological analysis soft-
ware (WinWCP version 4.5.7; Dempster, 1988).
All experiments were carried out at room temperature and
prior to the beginning of each experiment the sciatic nerve was
incubated in HEPES-based physiological salt buﬀer for 30 min
under constant super-maximal stimulation to demonstrate via-
bility and consistency in the action potential recordings. If the
action potential amplitude decreased by 10% the preparation
was either remounted in fresh Vaseline or discarded. Com-
pounds were added to the middle chamber (1 mM of CB[6],
CB[7], Motor2, β-cyclodextrin, cisplatin and cisplatin@CB[7]).
At the end of each experiment tetrodotoxin (TTX; 1 µg mL−1)
was added to the central chamber in order to determine the
extent of de-sheathing. Sciatic nerves with adequate de-sheath-
ing show a rapid decrease in the amplitude of their action
potential when treated with TTX. If the sciatic nerve was not
adequately de-sheathed the response to TTX is not as rapid
and the results for these nerves were not used in the data ana-
lysis. Measurements are expressed as the mean ± SEM (n = 3).
Isolated chick biventer cervicis nerve muscle preparation
(myotoxicity)
Chicks 3–15 days old were euthanised with CO2. The back of
their neck was plucked and the skin incised along the midline
from the skull to below the base of the neck exposing both of
the biventer cervicis muscle lying on either side of the
midline. A thread was tied round the upper tendon muscle
and a loop was tied at the bottom end of the neck muscle. The
muscle was then cut away and kept in the following Krebs–
Henseleit physiological salt buﬀer solution: 118 mM NaCl,
25 mM NaHCO3, 11 mM glucose, 4.7 mM KCl, 1.2 mM MgSO4,
0.3 mM KH2PO4, 2.5 mM CaCl2 and equilibrated with a gas
mixture of 95% O2, 5% CO2 to maintain a pH of 7.4. The loop
was used to attach the preparation in the organ bath and ring
electrodes were placed around the tendon to stimulate the
muscle indirectly.
Prior to the addition of test compound, two control com-
pound responses were obtained: 1 mM acetylcholine (ACh, 30 s)
and 30 mM KCl (30 s). These control compounds were then
washed by over flow with Krebs–Henseleit solution. After the
KCl response was obtained, the preparations were allowed to
equilibrate for 30 min before the addition of 300 µM of com-
pound (CB[6], CB[7], Motor2, β-cyclodextrin, cisplatin and cis-
platin@CB[7]). At the end of the experiment, the two control
responses were repeated to determine the change in postsyn-
aptic activity. Measurements are expressed as the mean ± SEM
(n = 3–8).
Contractile recordings from rat atria (cardiotoxicity)
Male Sprague Dawley rats weighing between 250–350 g were
killed by cervical dislocation and their heart was dissected and
maintained in cold Krebs–Henseleit physiological salt solution
and equilibrated with a gas mixture of 95% O2/5% CO2 to
maintain the pH at 7.4. The left and right atria were carefully
removed from the heart under a stereo-microscope and a small
loop was tied at one end of both atria and a knot at the other
end using a thin thread. The atria were then mounted into
separate 10 mL organ baths containing Krebs–Henseleit
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physiological salt solution, maintained at 37 °C and gassed
with 95% O2/5% CO2 throughout the experiment. In the organ
bath, one end of the atria was tied to a metal rod and the other
end was attached, via a cotton thread, to a Grass force displace-
ment transducer model FT03 connected to a powerlab/4SP
analogue-to-digital recording system (AD Instruments) and dis-
played on a computer running Windows XP.
The right atria beats spontaneously due to the sinoatrial
node, and a contraction was electrically evoked in the left atria
by field stimulation (4 Hz, 2 ms duration, 10–15 V strength:
Grass S88). A resting tension of 0.5 g was applied to both the
left and right atria and maintained throughout the exper-
iment. Prior to the start of each experiment, 10 µM noradrena-
line (NA) was added to the organ bath, and tissue that did not
respond was discarded. With the tissue that did respond, the
NA was washed out and the atria allowed to equilibrate for
30 min before the addition of test compound (300 µM of CB[6],
CB[7], Motor2, β-cyclodextrin, cisplatin and cisplatin@CB[7]).
Measurements are expressed as the mean ± SEM (n = 3–5).
Results and discussion
The safe dose of cucurbiturils in animals is dependent on the
size and type of the cucurbituril and its method of adminis-
tration. The lowest maximum tolerated dose for CB[7] is
250 mg kg−1 when administered by injection. Assuming a
model human size of 75 kg, then this equates to a concen-
tration of approximately 3.2 mM. Therefore, in this study we
have examined the toxicity of three diﬀerent cucurbiturils
(CB[6], CB[7] and Motor2) at a 1/3 and 1/10 of this maximum
dose, giving 1 mM and 300 μM solution concentrations,
respectively. To put the cucurbituril toxicity results into per-
spective they are compared with the known safe macrocycle,
β-cyclodextrin, which has no reported neuro-, myo- or cardio-
toxic side-eﬀects.
Neurotoxicity
A desheathed mouse sciatic nerve preparation was chosen as a
model to study the neurotoxicity of the macrocycles. The
desheathing process involved the careful removal of the outer
epineurium tissue that surrounds the nerve, thus allowing
direct access to the nerve cells by the macrocycles.
The natural drop-oﬀ in nerve conduction was evaluated
using a time control study that monitored the stability of the
electrically generated nerve compound action potential (nCAP)
over a period of two hours. Fig. 2 shows that within the first
40 min the sciatic nerve preparations are still 100% viable with
no change in the amplitude of the nCAP. By 80 minutes the
amplitude of the nCAP has decreased by only 5% ± 3.3 but by
120 minutes the sciatic nerve has lost 10% ± 4.2 of its viability.
As a result, the toxicity experiments were carried using macro-
cycle solutions of 1 mM over a period of 80 minutes to ensure
reliability of the results.
The results show that CB[7] and Motor2 induced a decrease
in nCAP amplitude by 4% ± 0.2 and 13% ± 1.5, respectively,
while CB[6] and β-cyclodextrin induced an increase in nCAP by
3% ± 4.6 and 7% ± 4.2, respectively (Fig. 3). β-Cyclodextrin is
not known to be neurotoxic, so the similar increase in nCAP by
CB[6] implies that the cucurbituril is probably not neurotoxic.
The decrease in nCAP by CB[7] is the same magnitude as the
natural drop-oﬀ in untreated samples indicating it is also not
neurotoxic. Whilst Motor2 decreased nCAP by 13% there is no
statistical diﬀerence (students paired t-test, p = 0.1) compared
with untreated nerve. As such, all three cucurbiturils appear to
display no neurotoxicity.
Eﬀect of CB[7] on the neurotoxicity of cisplatin
Neurotoxicity is one of the major dose limiting side eﬀects of
cisplatin. Studies have shown that cisplatin primarily accumu-
lates in the dorsal root ganglia (DRG) of neurons and predomi-
nantly induces sensory neuropathy characterised by severe loss
of proprioception (body movement), sensation of pins and
needles, and numbness of the feet.21–23
The eﬀect of CB[7] on the neurotoxicity of cisplatin was
investigated by analysing and comparing the eﬀect of 1 mM
cisplatin and cisplatin@CB[7] on the amplitude of nCAP.
The results show there is no statistical diﬀerence in the
neurotoxicity of cisplatin compared with cisplatin@CB[7]
(Fig. 4). At 80 min, cisplatin reduced the nCAP amplitude by
13% ± 4.7, which shows some neurotoxicity but not at the level
Fig. 2 The change in the amplitude of the nCAP of untreated sciatic
nerves over a period of two hours. At 80 minutes, the nerves have only
lost 5% of their normal conductance (n = 3).
Fig. 3 The change in nCAP amplitude of the sciatic nerve after treat-
ment with (blue) CB[6] (p = 0.3), (red) CB[7] (p = 0.7), (green) Motor2 (p
= 0.1) and (purple) β-cyclodextrin (p = 0.1) after 80 minutes.
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normally observed in the clinic. The reason for the lower toxi-
city is most likely because the sciatic nerve is composed
mainly of neuronal axons with smaller amounts of DRG,
which are predominantly located in the spinal cord. Therefore,
the low neurotoxicity caused by cisplatin in this experiment is
due to the low number of DRG.
The results for cisplatin@CB[7] are similar to free cisplatin
with a decrease in nCAP amplitude of 22.7% ± 6.6. The results
therefore indicate that CB[7] does not have a neuro-protective
eﬀect for cisplatin.
Myotoxicity
The myotoxic activity of the macrocycles was examined using
the isolated chick biventer cervicis nerve-muscle preparation.
Under ex vivo conditions the muscle can be forced to contract
using chemical or electrical stimulation. For chemical stimu-
lation, the addition of exogenous acetylcholine (ACh) or KCl
results in muscle contraction. The ACh acts by binding to nico-
tinic receptors located on the muscle membrane causing
depolarisation followed by contraction (post-synaptic eﬀect).
Potassium chloride causes muscle membrane depolarisation
resulting in calcium release into the synaptic cleft (the area
between nerve and muscle). The calcium then binds to neuro-
nal receptors which results in the release of ACh from the
neuron ultimately causing muscle contraction (pre-synaptic
eﬀect).
Baseline results for the force of muscle contraction was
determined using both electrical and chemical stimulation.
The nerve-muscle was then exposed to the macrocycles and
after two hours the force of muscle contraction was again
determined (Fig. 5). The macrocycles are myotoxic if they
demonstrate a statistically significant increase or reduction in
the force of muscle contraction compared with baseline
results. An increase in force of contraction due to exogenous
ACh indicates that the compound tested may have anticholi-
nesterase eﬀect; cholinesterase is an enzyme located in the
synaptic cleft that terminates signal transmission by breaking
down acetylcholine activity therefore prolonging/increasing the
eﬀect of ACh. An increase in the lifetime of ACh will synergisti-
cally increase/prolong the response to KCl.
After two hours, the untreated nerve-muscle’s response to
ACh, KCl and its electrically stimulated contraction had all
decreased by 4% ± 2, 18% ± 5 and 11% ± 5, respectively. Cucur-
bit[6]uril increased nerve-muscle response to ACh by 10% ±
10, and decreased its response to KCl and electrical stimulated
contraction by 24% ± 17 and 20% ± 4, respectively. Cucurbit[7]
uril decreased the nerve-muscle’s response to ACh, KCl and
the electrically stimulated contraction by 21% ± 10, 51.8% ± 8
and 84% ± 9, respectively. The cucurbituril-derivative, Motor2,
increased nerve-muscle response to both ACh and KCl by (37%
± 12) and (2% ± 12), respectively, and decreased its electrically
stimulated contraction by 15% ± 13. β-Cyclodextrin increased
nerve-muscle response to ACh by 20% ± 7, decreased its
response to KCl by 15% ± 9, and increased its electrical stimu-
lated contraction by 11% ± 10.
Overall the largest myotoxic eﬀect was observed after nerve-
muscle exposure to CB[7]. Significant decreases in activity are
apparent for KCl (p = 0.05) and electrical stimulation (p =
0.01), this indicates that CB[7] may be binding to and blocking
the postsynaptic muscle’s nicotinic receptors and therefore
interfering with the depolarisation ability of the membrane. A
small decrease in twitch via electrical stimulation is also
observed after exposure to CB[6] (p = 0.3) although the
decrease is considerably smaller in magnitude compared with
CB[7]. Given that β-cyclodextrin also results in a decrease of
electrically stimulated contraction (p = 0.9), and it is not a
known myotoxic compound, the results may suggest that the
electrical stimulation results for CB[6] and CB[7] are statisti-
cally decreased, however this may not result in in vivo toxicity.
Eﬀect of CB[7] on the myotoxicity of cisplatin
The eﬀect of CB[7] on the myotoxicity of cisplatin was investi-
gated by analysing and comparing the eﬀect of cisplatin and
cisplatin@CB[7] on the response of the nerve-muscle’s chemi-
cal and electrical stimulation.
The results show that cisplatin induced significant myo-
toxic activity when measured using both chemical and electri-
Fig. 4 The diﬀerence in the change of nCAP amplitude of the sciatic
nerve after treatment with 1 mM of (blue) free cisplatin (p = 0.3) and
(red) cisplatin@CB[7] (p = 0.1).
Fig. 5 The nerve-muscle’s responses to (grey) ACh, (green) KCl and
(purple) the electrically stimulated contraction at two hours after
exposure to macrocycle for untreated nerves (n = 3), CB[6] (n = 3), CB[7]
(n = 4), Motor 2 (n = 3) and β-cyclodextrin (n = 3).
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cal stimulation (Fig. 6). Free cisplatin increased nerve-muscle
contraction force to ACh and KCl by (96% ± 32, p = 0.005) and
(121% ± 3, p = 0.001), respectively, and decreased the force of
its electrically stimulated contraction by 96% ± 4 (p = 0.001)
which is consistent with the peripheral neuropathy known to
occur with cisplatin chemotherapy. The results also suggest
that cisplatin may have anticholinesterase activity as demon-
strated in previous studies and that this may also contribute in
part to the neurotoxic side eﬀects of cisplatin.24 Encapsulation
of cisplatin by CB[7] decreased nerve-muscle response to
ACh by 17% ± 6 (p = 0.4), and increased its response to KCl
by 59% ± 27 (p = 0.2). Cucurbit[7]uril showed a myo-protective
eﬀect as cisplatin@CB[7] decreased the electrical
stimulated muscle contraction by only 36% ± 12 (p = 0.04)
only; this is a reduction of the myotoxic activity of free cispla-
tin by 60%.
Cardiotoxicity
Heart atria from rats were used as a model to study the cardio-
toxic activity of the macrocycles. The right atrium contains a
natural pacemaker called the sinoatrial (SA) node which
causes the atrium to contract naturally; however, such a pace-
maker is absent in the left atrium and electrical stimulation is
needed to initiate contraction.
Both atria were treated with each of the four macrocycles
for a period of two hours. The function of the atria was studied
by monitoring both the rate of atria contraction (BPM, beats
per minute) and force of contraction (amplitude of
contraction).
In the untreated atria (control), the results show that by the
end of the experiment the left atrium was more stable than the
right as no changes were observed in either its rate or force of
contraction (Fig. 7). In contrast, after two hours the rate and
force of right atrium contraction had increased by 8% ± 1 and
16% ± 1.9, respectively.
The cardiotoxicity results show that each cucurbituril por-
trayed significant cardiotoxic activity with Motor2 being the
most cardiotoxic (Table 1). All of the macrocycles induced
greater changes in the force of contraction compared with the
contraction rate. Changes in the force of contraction are seen
within the first 15–30 minutes after exposure to macrocycle,
whereas a longer period of time (30–45 minutes) is required
before changes in the rate of contraction are observed (Fig. 8).
Eﬀect of CB[7] on the cardiotoxicity of cisplatin
Although uncommon, there are various clinical studies that
have reported cardiotoxic eﬀects of cisplatin. Toxicity occurs in
Fig. 6 The eﬀect of cisplatin (n = 4) and cisplatin@CB[7] (n = 8) on the
nerve-muscle’s response to (grey) ACh, (green) KCl and (purple) the
amplitude of its electrically stimulated contraction after two hours of
exposure to macrocycle.
Fig. 7 The change in atria contraction rate (top panel) and force of
contraction (bottom panel) in untreated right (dark red, dark blue) and
left atria (light red, light blue) over a period of two hours.
Table 1 A summary of the cardiotoxic changes induced by each macrocycle on the rate and force of both right and left atria contraction. The posi-
tive and negative signs indicate an increase or decrease in rate and force of contraction, respectively. The statistical signiﬁcance of each result is
given (p score based on student’s paired t-test)
Macrocycle (300 μM)
Percent change in rate of contraction Percent change in force of contraction
Right atrium Left atrium Right atrium Left atrium
CB[6] +12 ± 6 (p = 0.3) +3.3 ± 1 (p = 0.3) −41.7 ± 19.7 (p = 0.06) −55 ± 6.1 (p = 0.06)
CB[7] +31 ± 13.6 (p = 0.2) −10 ± 3.5 (p = 0.4) −29 ± 3.4 (p = 0.02) −18 ± 6.8 (p = 0.3)
Motor2 +30 ± 19 (p = 0.4) +15 ± 3.8 (p = 0.2) −68 ± 3.1 (p = 0.001) −60 ± 5.4 (p = 0.008)
β-Cyclodextrin +32 ± 12 (p = 0.2) +3 ± 3 (p = 0.5) +1 ± 3.3 (p = 0.09) −33 ± 4.1 (p = 0.04)
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the form of atrial or ventricular arrhythmias, tachycardia,
bradycardia and conduction abnormalities. Most of these
cardiac problems are reported to be clinically silent and occur-
ring within hours of drug infusion.25–27
The protective eﬀect of CB[7] on the cardiotoxic activity of
cisplatin was investigated using free cisplatin and cispla-
tin@CB[7] in the unpaced right atrium. The right atrium was
chosen for this study as cisplatin exhibited no cardiotoxic
activity in the left paced atrium (data not shown).
The results show that cisplatin induced cardiotoxic activity
by reducing both the rate and force of contraction by 68.8% ±
8.4 (p = 0.07) and 53.7% ± 17.0 (p = 0.2), respectively (Fig. 9).
Furthermore, cisplatin induced a gradual and dramatic
increase in the atria’s force of contraction by 250% within the
first 60 min, after which it was reduced by 54% by the end of
the experiment. When encapsulated by CB[7], the cardiotoxic
activity of cisplatin was significantly reduced; cisplatin@CB[7]
induced only an 11% ± 5.6 (p = 0.2) decrease in the rate of
Fig. 8 The changes in the rate and force of contraction in both the right (dark red, dark blue) and left atria (light red, light blue) when treated with
300 μM of (a) CB[6], (b) CB[7], (c) Motor2 or (d) β-cyclodextrin over a period of two hours.
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atria contraction, and increased the force of contraction by
only 27% ± 18.0 (p = 0.2). As well as reducing the magnitude of
change in rate of contraction, CB[7] also stabilised the force of
contraction compared to free cisplatin. After 60 min the force
of contraction increased by just 27% ± 18.0 and was main-
tained at this magnitude throughout the experiment.
Conclusion
In this study, the cucurbituril macrocycles CB[6] and CB[7]
and their derivative, Motor2, were tested for their neuro-, myo-
and cardiotoxic activity and the results compared with the
known safe β-cyclodextrin using ex vivo models.
The results show that all of the macrocycles showed no
neurotoxic activity within the time frame tested as there was
no statistically measurable diﬀerence between the changes in
nCAP induced by the cucurbiturils compared to that caused by
β-cyclodextrin or control. In the myotoxicity study, CB[7]
showed the greatest myotoxic activity by causing the greatest
reduction in the electrically stimulated nerve-muscle contrac-
tion, whilst Motor2 and β-cyclodextrin displayed the least myo-
toxic activity. All of the macrocycles showed cardiotoxic activity
by predominantly reducing the force of atria contraction com-
pared to changes in the rate of its contraction, with Motor2
being the most cardiotoxic.
The eﬀect of drug encapsulation by CB[7] on these specific
tissue toxicities was tested using the platinum-based anti-
cancer drug cisplatin. While free cisplatin displayed toxicity to
all three tissue types, when encapsulated by CB[7], the extent
of its myo- and cardiotoxic activity were significantly reduced
while no statistical change in toxicity was seen in the neuro-
toxicity studies. These ex vivo results are consistent with the
lack of acute systemic toxicity seen by for CB[n]s when pre-
viously tested for their in vitro and in vivo systemic toxicities
and also show the advantages of using CB[7] as a drug delivery
vehicle in providing protection from some of the side eﬀects
associated with the platinum-based drugs.
Overall, whilst some toxicity of the macrocycles was
observed for myo- and cardio toxicity, these experiments re-
present very high doses with direct access to the tissues. In a
human clinical setting, the dose used will be 2- to 10-fold
lower. For example, if used as a protective agent for cisplatin
then the actual dose of CB[7] will be 80 to 160 µM (assuming a
cisplatin dose of 60 to 120 mg m−2).28 From this, much of the
dose will be quickly cleared via the kidneys and the dose to
which the nerves, muscle and heart will be exposed will be sig-
nificantly lower still. The results, however, do warrant further
investigation into the toxicity of CB[n]s to establish their
safety.
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